Visual acuity and electroretinography findings 3 ½ years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity
2011

Visual Acuity and ERG Findings After Bevacizumab Injection in Premature Infants

Sample size: 1 publication Evidence: low

Author Information

Author(s): Shah Parag K, Morris Rodney J, Narendran V, Kalpana N

Primary Institution: Aravind Eye Hospital and Postgraduate Institute of Ophthalmology

Hypothesis

Does intravitreal injection of bevacizumab affect visual acuity and electroretinography in infants with aggressive posterior retinopathy of prematurity?

Conclusion

Intravitreal bevacizumab does not adversely affect electroretinography but may impact final visual acuity.

Supporting Evidence

  • Bevacizumab injection led to dramatic improvement in anterior segment ischemia.
  • Visual acuity improved to 20/30 in the right eye but remained poor in the left eye.
  • Electroretinography showed extensive damage to rods and bipolar cells.

Takeaway

A baby with a serious eye condition got a special eye injection, and while it helped some things, it didn't make his vision as good as hoped.

Methodology

The study involved a case report of a single infant who received an intravitreal injection of bevacizumab and was followed up for visual acuity and ERG findings.

Potential Biases

Potential bias due to the lack of a control group and reliance on a single case report.

Limitations

The study is based on a single case, limiting the generalizability of the findings.

Participant Demographics

A male infant born at 31 weeks of gestation with a birth weight of 1170 g.

Digital Object Identifier (DOI)

10.4103/0301-4738.73707

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication